COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Optimizing the Effectiveness of Routine Post-treatment Surveillance in Prostate Cancer Survivors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02957357
Recruitment Status : Unknown
Verified March 2018 by Alliance Foundation Trials, LLC..
Recruitment status was:  Active, not recruiting
First Posted : November 6, 2016
Last Update Posted : March 20, 2018
Patient-Centered Outcomes Research Institute
Information provided by (Responsible Party):
Alliance Foundation Trials, LLC.

Brief Summary:
Through this study, the investigators seek to identify the benefits (improved survival) and harms (more procedures, more treatment, side effects, and quality-of-life impact) from different surveillance frequencies—every three vs. six vs. 12 months. Using the National Cancer Database and quality-of-life data from a large group of prostate cancer survivors, the investigators aim to compare survival, procedures/tests, treatments, and side effects in prostate cancer survivors who are followed with alternative surveillance frequencies and compare quality-of-life outcomes. The overall goal of the study is to provide high-quality data that will allow development of a personalized, risk-based tailored approach to post-treatment surveillance for prostate cancer.

Condition or disease
Cancer of Prostate Cancer of the Prostate Prostate Cancer Prostatic Cancer

Layout table for study information
Study Type : Observational
Estimated Enrollment : 14000 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Optimizing the Effectiveness of Routine Post-treatment Surveillance in Prostate Cancer Survivors
Study Start Date : February 2016
Estimated Primary Completion Date : August 2018
Estimated Study Completion Date : January 31, 2019

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Mortality (all cause) [ Time Frame: 2-10 Years after treatment ]

Secondary Outcome Measures :
  1. Time to recurrence [ Time Frame: 2-10 Years after treatment ]
  2. Treatment for recurrent cancer [ Time Frame: 2-10 Years after treatment ]

Other Outcome Measures:
  1. Patient-reported anxiety [ Time Frame: 2-10 Years after treatment ]
  2. Health-related quality of life [ Time Frame: 2-10 Years after treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

A total of 14,000 prostate cancer patients in the National Cancer Data Base (nationwide cancer registry) will be analyzed.

The investigators will analyze data from the National Cancer Data Base (NCDB), a cancer registry which is maintained by the American College of Surgeons Commission on Cancer (CoC). Cancer registry staff review hospital and provider records to collect necessary data for the cancer registry so data are available for analysis for this project. There are >1400 CoC-hospitals; 10 patients will be sampled at each hospital thus 14,000 patients will be available for analysis.


Inclusion Criteria:

  • Patient data part of the NCDB
  • Diagnosed with prostate cancer in 2004-2005.
  • Treated for prostate cancer with surgery (prostatectomy) or radiation therapy

Exclusion Criteria:


Layout table for additonal information
Responsible Party: Alliance Foundation Trials, LLC. Identifier: NCT02957357    
Other Study ID Numbers: AFT-30
First Posted: November 6, 2016    Key Record Dates
Last Update Posted: March 20, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: The investigators do not plan to share data or to make individual participant data available.
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases